JOINT WORKING EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk
Joint Working between AstraZeneca UK Ltd and Mid Yorkshire Teaching NHS Trust
Document Number: JW-456-1-ESI

Project title	MY-STEER: Mid Yorkshire – Symptom and Treatment Evaluation in Emergency and prehospital Response in patients with asthma
Aims and Objectives	The overall aim of the project will be to improve access to guideline-directed asthma and severe asthma treatment as well as reduce the existing reliance on costly acute care. Objectives: - Increase in the number of patients referred and reviewed at the Severe Asthma MDT for consideration of biologic therapy. - Increase in patients managed in line with current West Yorkshire asthma guidelines - Reduction in healthcare resource utilisation (HRCU) both in A&E and through West Yorkshire Ambulance Service - Establish community outreach to areas of low service utilisation (e.g. GP practices) to educate patients and clinicians - Streamlined pathway for Mid Yorkshire to address the needs of these Asthma patients with reduced access to established medical care; evidenced by time to treatment and caseload distribution - Review 500 high risk high HRCU patients
Anticipated benefits	**Patient Benefits:** Benefits for Patients Earlier identification of patients with uncontrolled asthma and those who may be eligible for biologic therapies, enabling timely intervention and treatment optimisation. Improved symptom control and a reduction in asthma exacerbations. Increased access to specialist respiratory support within community-based settings. Enhanced quality of life through better disease management and reduced reliance on short-acting beta agonists (SABA). **NHS Benefits**

	Reduced pressure on urgent and emergency care services through fewer asthma-related A&E attendances and ambulance callouts. More efficient use of high-cost biologic therapies through the timely and appropriate identification of eligible patients. Release of consultant capacity through the enhanced role of specialist nurses, allowing secondary care resources to focus on patients with the most complex needs. Improved alignment with national asthma guidelines, quality standards, and best practice recommendations. Greater opportunity to deliver proactive, preventative care rather than reactive management of asthma exacerbations. **AstraZeneca Benefits** Contribution to improved patient outcomes through earlier intervention and optimised disease management. Support for more equitable access to advanced asthma therapies across the local population. Generation of high-quality real-world evidence and service-level insights to inform future pathway development. Opportunity to demonstrate the impact of innovative models of care and support wider service transformation initiatives. Development of a scalable approach that could be adapted for use across other respiratory disease areas in the future.
Timeline	The project will commence on the 19 October 2026 and will continue for a duration of 15 months.
References	
Contributions	The project will include the pooling of skills, experience and resources from both parties. AstraZeneca will provide funding for Clinical capacity band 7 nurse and AZ employee time for Project management and evalutaion at a total cost of £82,773.24 Mid Yorkshire Teaching NHS Trust is contributing Project management, Clinical capacity, clinical investigations, project evaluation at a total cost of £99,168.44 . Mid Yorkshire Teaching NHS Trust contribution does not include transfer of monies; it is based on cost of resource allocation. Full details of contributions are included in the agreed Joint working agreement with the NHS